Compare Airbnb, Inc. (ABNB) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Airbnb, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Airbnb, Inc. trades at $184.71 (market cap $110.60B), while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap. Which is the better fit depends on your goals.
| ABNB | VRTX | |
|---|---|---|
Market Cap | $110.60B | $132.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $184.98 | $529.65 |
52-Week Low | $111.54 | $376.62 |
Enterprise Value | $101.02B | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Airbnb (ABNB) is trading at $178.07, up 17.43% with strong momentum after Q2 2026 earnings beat expectations. The stock is approaching four-year highs with bullish technical indicators and positive analyst sentiment. Revenue growth accelerated to $12.24B in 2025 with robust 82.9% gross margins, though recent quarters showed mixed earnings performance with two misses and one beat.
Outlook remains positive with AI-driven growth initiatives and expanding service offerings, but elevated valuation multiples (P/E 40.66) and competitive pressures present risks. Analyst consensus leans bullish with 46.7% buy ratings and $173.26 price target, though current price exceeds consensus target by 2.8%.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Airbnb, Inc.
Airbnb, Inc. operates an online marketplace for travel information and booking services. The Company offers lodging, home stay, and tourism services via websites and mobile applications. Airbnb serves clients worldwide.
Read more on ABNB →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
